Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Table 3 Effects of study medication on biomarker serum levels

Serum biomarker and study group		Level changes^a
Serum biomarker and study group		Δδ day 14 of cycle 1 - baseline	P value	Δδ day 1 of cycle 2 - baseline	P value	Δδ day 1 of cycle 3 - baseline	P value
VEGF-A	Sunitinib	-0.6816 (1.43)	0.017	-0.1393 (1.83)	0.831	0.1111 (1.26)	0.975
VEGF-A	Placebo	-0.3134 (1.24)	0.472	-0.7184 (1.32)	0.033	-1.1177 (1.92)	0.062
sVEGFR2	Sunitinib	-0.0648 (0.17)	0.012	-0.0854 (0.12)	0.006	-0.0727 (0.14)	0.078
sVEGFR2	Placebo	-0.0086 (0.12)	0. 222	-0.0216 (0.10)	0.472	0.0306 (0.20)	0.910
VEGF-D	Sunitinib	0.2476 (0.26)	<0.001	0.1038 (0.27)	0.131	0.0914 (0.20)	0.133
VEGF-D	Placebo	-0.1093 (0.66)	0.616	-0.0094 (0.19)	0.811	-0.1061 (0.25)	0.281
SDF-1α	Sunitinib	0.0914 (0.47)	0.756	0.2912 (0.92)	0.730	-	-
SDF-1α	Placebo	-0.0827 (0.93)	0.820	0.3572 (0.85)	0.041	-	-

^aData are presented as mean (SD). P < 0.05 marked in boldface and considered significant using paired Wilcoxon test